Articles tagged with Immune Response
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
A new study from the La Jolla Institute for Immunology reveals that two groups of regulatory CD4+ T cells develop at different times to combat acute inflammation. The early Tregs reduce autoimmune damage, while the second wave shuts down the entire immune response to signal infection clearance.
A recent study found that a subset of immune cells within the alveolar bone marrow were activated by the presence of commensal oral microbes, leading to increased osteoclast-mediated bone resorption and bone loss. Reducing the burden of commensal microbes through oral antiseptic rinses can help protect against alveolar bone loss.
Researchers at Johns Hopkins Medicine discovered a peptide on the SARS-CoV-2 spike protein that triggers an immune response in humans and is also recognized by cells of the immune system, suggesting potential for protection against future zoonotic outbreaks. The study supports the development of multivalent vaccines against a broad spe...
Researchers tracked antibody response to COVID-19 vaccination and found that antibodies improve in quality for months after vaccination. Even low levels of antibodies provide some protection as long as the virus doesn't change.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
A new study finds that certain COVID-19 variants can escape the human immune system's cytotoxic T cell response in a significant portion of the population. The researchers identified 1,222 epitopes associated with major HLA subtypes, covering about 90% of the human population.
A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Scientists sequenced the gene expression profiles of more than 170,000 individual cells to shed light on a key mystery: the role of Type I Interferons (IFN) during viral infections. The study reveals interferon plays a crucial role in clearing the virus by alerting immune cells, such as macrophages, to search and destroy infected cells.
Researchers found that current COVID-19 vaccines provide robust protection against severe disease caused by the Omicron variant through induced cellular immunity. The study showed that CD8+ T cell responses were over 80% cross-reactive with the original strain, suggesting a key role in vaccine protection.
A study by UConn Health and Washington University School of Medicine found that eating more meat correlates with worse MS symptoms, altered gut bacteria, and increased immune cells. The research identified key bacteria and metabolites associated with the disease, providing new insights into its causes.
Researchers at UC Riverside have identified a new host protein interaction in chickens that triggers a strong immune response against viral infections. The discovery sheds light on the differences between bird and human immune responses to zoonotic viruses.
A new study finds that breakthrough infections following vaccination and natural infection followed by vaccination provide roughly equal levels of enhanced immune protection. Researchers at OHSU found that both groups generated greater levels of immunity compared to those who were vaccinated with no infection.
Researchers found a distinct microbial profile associated with long COVID symptoms, including fatigue, muscle weakness, and insomnia. Patients with long COVID had a less diverse and abundant gut microbiome compared to those without the condition.
A new study reveals the Beta variant of SARS-CoV-2 can elicit a wide range of antibodies effective against both Delta and Omicron variants. The findings suggest that vaccination strategies could be improved by leveraging this broad immunity.
Immunosequencing of T cells combined with machine learning techniques reveals that participants with higher numbers of pre-existing memory CD4 T cells develop immunity more quickly and produce more antibodies following vaccination. This study has significant implications for immunity and vaccine development efforts.
A recent study found that individuals vaccinated three times or those who were vaccinated after an earlier COVID-19 infection had comparable neutralizing antibody activity to those with a breakthrough case. The study suggests that repeated exposure to SARS-CoV-2 antigens enhances the quality of antibody responses.
The four-year programme will investigate the chemical signatures that trigger immunity in fungal infections, which kill an estimated 1.6 million people worldwide annually. By understanding these signatures and how fungi disguise them, researchers hope to uncover the origins of antifungal immunity.
A study by Mayo Clinic researchers found that cancer patients receiving chemotherapy and targeted therapies may mount inadequate immune responses to COVID-19 vaccination. The authors recommend antibody level testing and booster vaccinations for these patients.
Researchers at the Josep Carreras Leukaemia Research Institute and the Germans Trias i Pujol Hospital discovered that vitamin D activates the tolerance program of dendritic cells through epigenetic modification. This finding offers new hope for treating autoimmune diseases like multiple sclerosis by optimizing tolerogenic dendritic cells.
Northwestern University scientists have identified a key mechanism used by the Zika virus to evade the antiviral response of host cells. The study reveals how the virus suppresses interferon signaling to gain access to cells, providing a new target for antiviral therapeutics.
Researchers at Lund University discovered that non-neutralising antibodies can also protect against Covid-19 by facilitating phagocytosis. The findings suggest that broader protection from antibodies may be more effective in combating mutations of the virus.
Researchers discovered that pathogens can hijack mitochondrial defense mechanisms by mimicking host proteins, effectively disarming the mitochondria. This allows the pathogen to acquire essential nutrients and evade the host's immune response.
Researchers discovered the ZIP-1 gene acts as a cell's first-line response to infection, controlling immune responses to viruses and other threats. The finding could have implications for identifying similar genes that control immune responses in humans.
The Sanford Children's Genomic Medicine Consortium has initiated a whole genome sequencing research project to investigate undiagnosed illnesses in children with suspected inborn errors of immunity. The study aims to sequence the genomes of up to 25 patient genomes and learn information that can benefit patients and others.
Patients with skin-related side effects from immune checkpoint inhibitors tend to live longer, with a 22-50% decrease in mortality. These findings suggest that skin toxicities can be an indicator of treatment efficacy and may help identify patients who are more likely to benefit from their current immunotherapy regimen.
A large population study found that living alone for several years and/or experiencing serial relationship break-ups are strongly linked to raised levels of inflammatory markers in the blood of middle-aged men. The researchers suggest that this combination may indicate a heightened risk of age-related ill health and death.
Researchers found that people infected with COVID-19 develop a wide variety of autoantibodies up to six months after recovery, and these autoantibodies persist over time. The study suggests that understanding these autoantibody responses could help identify ways to treat and prevent long-term symptoms.
A new study reveals that mRNA vaccines activate a type of helper cell called T follicular helper cells, which assist in creating powerful antibodies and drive the development of immune memory. This strong response helps prevent severe disease and death, even against highly mutated variants like omicron.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
A new study found that infection-fighting B cells retain better memory of the coronavirus spike protein in patients who recover from less-severe cases of COVID-19 than those recovering from severe cases. This hints at subtle differences in the quality of immune response based on COVID-19 severity.
A global study found that hospitalized COVID-19 patients with metabolic syndrome had a 20% higher risk of developing acute respiratory distress syndrome (ARDS) and dying. The study examined records of over 46,000 patients in 181 hospitals across 26 countries.
A new study reveals the sophisticated mechanism by which adenoviruses infect human cells and transfer foreign DNA into their nucleus. Protein V plays a crucial role in increasing the virus particle's stability and preventing premature DNA release, which triggers an anti-viral alarm system.
Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.
A new study suggests that breakthrough infections generate 'super immunity' to COVID-19, providing a robust immune response against the delta variant and potentially other variants. The study found that antibodies generated from breakthrough cases were 1,000% more effective than those from vaccinated individuals.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.
Researchers at Mayo Clinic found that mRNA therapy improves the response of patients who weren't responding to cancer immunotherapy. The study identified a weak spot in T cells, white blood cells crucial for fighting cancer, and developed an mRNA-based strategy to enhance their response.
Researchers have discovered a fundamental role of the TBK1 enzyme in deciding B cell fate, crucial for developing effective vaccines for diseases like COVID-19 and malaria. The study reveals that TBK1 is necessary for germinal center formation and high-quality antibody production.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.
A novel vaccine, TOH-Vac1, replicates inside the body's cells and generates a powerful immune response in mice and monkeys. The vaccine is based on a strain of vaccinia virus used to vaccinate against smallpox and can be programmed to protect against multiple variants.
A landmark study found that convalescent plasma was safe and effective in treating early COVID-19 patients, particularly those with weakened immune systems. The trial showed improved outcomes in patients given high-titer plasma during the first quarter of the pandemic.
Researchers at La Jolla Institute for Immunology identified Th1* cells as a key marker in the body's immune signature following BCG vaccination. The study found that these cells respond well to the vaccine and can help fight the Mycobacterium tuberculosis bacterium that causes TB.
A new study reveals that infant immune systems are robust and efficient, allowing them to quickly respond to new pathogens. This may explain why infants are less affected by COVID-19 than adults, who take longer to react.
Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.
Researchers discovered that blood stem cells use high-energy fatty acids from the body's fat stores to power up their response to infection. This finding could lead to new approaches in treating bacterial infections, particularly in vulnerable and older individuals.
Researchers at Hokkaido University and Texas A¼M University identified a key mechanism used by SARS-CoV-2 to evade host immune systems, targeting the MHC class I pathway. The study found that the virus suppresses the activation of this pathway using the ORF6 protein, allowing it to persist in the body and infect others.
Researchers at Illinois provided insight into the signal transduction mechanism utilized by Staphylococcus aureus's TCS ArlRS in response to host-imposed manganese and glucose starvation. The study found that histidine kinase ArlS is necessary for activation of response regulator ArlR under both manganese and glucose-limited conditions.
A new particulate saponin/TLR agonist vaccine adjuvant has been shown to alter lymph flow and modulate adaptive immunity. This study demonstrates the potential of this ingredient as a more effective vaccine booster.
A study by Imperial College London found that the first SARS-CoV-2 spike protein encountered through vaccination or infection influences subsequent immune responses to current and future variants. This 'immune imprinting' affects the rate of decay of protection and impacts antibody levels over time.
Researchers found that macrophages play a central role in COVID-19-related respiratory failure, leading to fibroproliferative ARDS and prolonged ventilation. Extensive tissue damage and scar tissue formation are characteristic of severe lung failure.
A recent study published in PLOS Pathogens found that the COVID-19 Delta variant may have a reduced ability to be neutralized by vaccines. The researchers analyzed serum samples from vaccinated individuals and found that the Delta variant was more effective at evading vaccine-induced immunity than other variants, such as Beta and Alpha.
A Canadian study found that delaying the second dose of an mRNA COVID-19 vaccine produces a stronger immune response, which could inform international vaccination strategies. This longer dose interval strategy enables early access to first doses and ensures better protection with the two-dose series.
Scientists discovered that fungal endophytes convert chitin to chitosan, a natural plant defense activator, to evade host defense. This conversion enables the fungus to live in symbiotic association with grasses, protecting them from biotic and abiotic stresses.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Antibodies that mimic the SARS-CoV-2 virus may explain lingering symptoms of long-haul COVID-19 and rare vaccine side effects like allergic reactions and blood-clotting. This theory, based on classic immunological concepts, suggests a cascade of immune responses that can lead to adverse effects.
Previous antibody responses to harmless coronaviruses contribute to SARS-CoV-2 immunity, reducing infection severity and hospitalization rates. Researchers found that people with strong immune responses to other human coronaviruses have some protection against SARS-CoV-2 infection.
A study found that individuals under 65 had higher antibody levels than those over 65, with women outperforming men. However, by six months post-vaccination, antibody levels dropped significantly for everyone in the study group.
People taking immunosuppressants, especially TNF inhibitors, have a weaker antibody response to COVID-19 vaccines. A third dose can drive antibody levels back up, but the duration is unknown.